Mathematical modelling approaches have become increasingly abundant in cancer
research. The complexity of cancer is well suited to quantitative approaches as it provides …

The use of advanced molecular profiling to direct the use of targeted therapy, such as
tyrosine kinase inhibitors (TKIs) for patients with advanced-stage non-small-cell lung cancer …

All patients with metastatic lung, colorectal, pancreatic or head and neck cancers who
initially benefit from epidermal growth factor receptor (EGFR)-targeted therapies eventually …

The success of tyrosine kinase inhibitors (TKIs) in select patients with non–small-cell lung
cancer (NSCLC) has transformed management of the disease, placing new emphasis on …

A key goal of cancer therapeutics is to selectively target the genetic lesions that initiate and
maintain cancer cell proliferation and survival. While most cancers harbor multiple …

Acquired drug resistance is a major limitation for the successful treatment of cancer.
Resistance can emerge due to a variety of reasons including host environmental factors as …

The development of targeted therapies has revolutionized the treatment of cancer patients.
The identification of “druggable” oncogenic kinases and the creation of small-molecule …

Drug resistance significantly limits the long-term effectiveness of targeted therapeutics for
cancer patients. Recent experimental studies have demonstrated that cancer cell …

Importance Variability in prescribed doses of 6-mercaptopurine (6MP) and lack of
adherence to a 6MP treatment regimen could result in intra-individual variability in systemic …

Acquired resistance is one of the major barriers to successful cancer therapy. The
development of resistance is commonly attributed to genetic heterogeneity. However …